Tolerability and Effectiveness of Tirzepatide in Kidney Transplant Recipients: Real-world Experience From a Single-center Study.
Tirzepatide just got a real-world test run in kidney transplant recipients, and the results are in: the peptide holds up. Researchers at the University of Pennsylvania tracked how kidney transplant patients handled tirzepatide, a GLP-1/GIP receptor agonist that’s been making waves for its effects on weight and blood sugar. Instead of staying in the theoretical zone, this team put tirzepatide in action with people who have unique and challenging metabolic profiles.
Transplantation
by Hussain SM, Malat G, Tandukar S et al.
“Tolerability and Effectiveness of Tirzepatide in Kidney Transplant Recipients: Real-world Experience From a Single-center Study. Hussain SM(1)(2), Malat G(2)(3), Tandukar S(1)(2), Trofe J(1)(2)(3), Potluri V(1)(2), Lim MA(1)(2). Author information: (1)Division of Renal Electrolyte and Hypertension, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. (2)Penn Transplant Institute, Hospital of the University of Pennsylvania, Philadelphia, PA. (3)Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, PA. Conflict of interest statement: The authors declare no conflicts of interest.”
Here’s why this matters. Managing weight and glucose after a kidney transplant is notoriously difficult. Standard approaches often don’t cut it, and researchers are always on the lookout for new tools. Tirzepatide already has a buzz for its dual-action on glycemic control and body weight, but transplant recipients are a whole different ballgame—immunosuppression, metabolic shifts, the works.
Key takeaways:
Tirzepatide was well-tolerated by kidney transplant recipients. No unexpected safety issues popped up.
The peptide delivered on effectiveness. Patients saw improvements in both weight management and glycemic control.
These results came from a real-world, single-center setting, not a tightly controlled clinical trial. Translation: this is what happens in regular practice.
Researchers didn’t just play it safe—they put tirzepatide through its paces in a group that often gets left out of early studies. The fact that patients handled it well and saw measurable benefits is a win for the peptide research community.
Anyone interested in the technical side or looking to dig deeper into tirzepatide data can check out the main peptide page here: tirzepatide. For those sourcing research compounds or comparing peptide vendors, the vendor directory is worth a look.
Bottom line: Tirzepatide keeps showing value, even in complex clinical scenarios. The research community isn’t done with this one yet.
Related Reading
Reply: Semaglutide in Frail HFpEF: Need for Objective Functional Measures and Body Composition Assessment.
News · JACC Heart FailSemaglutide in Frail HFpEF: Need for Objective Functional Measures and Body Composition Assessment.
News · NeuropsychopharmacologyIdentification of an intrusive-hypervigilant phenotype of posttraumatic stress symptoms with unique stress peptide and amygdala functional connectivity profiles.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.